Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)
Open Access
- 11 August 2026
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (8) , 38-43
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 18 references indexed in Scilit:
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2025
- Tarlatamab for Patients with Previously Treated Small-Cell Lung CancerNew England Journal of Medicine, 2023
- Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and EtoposideJournal of Thoracic Oncology, 2022
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANESMO Open, 2022
- Small-cell lung cancerNature Reviews Disease Primers, 2021
- Olaparib for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2020
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerNew England Journal of Medicine, 2019
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerNew England Journal of Medicine, 2019
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationNew England Journal of Medicine, 2017
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialThe Lancet Oncology, 2014